WebmedCentral.com :: Article Review View

Submited on: 11 Nov 2010 06:18:31 PM GMT

Published on: 13 Nov 2010 05:29:21 PM GMT

Posted by Dr. Abu Dzarr on 15 Nov 2011 04:54:30 AM GMT

1	Is the subject of the article within the scope of the subject category?	Yes
2	Are the interpretations / conclusions sound and justified by the data?	Yes
3	Is this a new and original contribution?	Yes
4	Does this paper exemplify an awareness of other research on the topic?	Yes
5	Are structure and length satisfactory?	Yes
6	Can you suggest brief additions or amendments or an introductory statement that will increase the value of this paper for an international audience?	No
7	Can you suggest any reductions in the paper, or deletions of parts?	No
8	Is the quality of the diction satisfactory?	Yes
9	Are the illustrations and tables necessary and acceptable?	Yes
10	Are the references adequate and are they all necessary?	Yes
11	Are the keywords and abstract or summary informative?	Yes

Other Comments:
Good unique report.

I wonder if she was given prophylactic oral antibiotics during grade 4 neutropenia. This was not mentioned in the manuscript. It will be interesting to know.

‘In case of life-threatening bleeding terlipresin and recombinant activated factor VII (rFVIIa) were prepared’. Did she ever require this measure? How many times.
Competing interests:
No
Invited by the author to review this article? :
No
Have you previously published on this or a similar topic?:
No
References:
None
Experience and credentials in the specific area of science:

Clinical expereince in Hemato Oncology.
How to cite: Dzarr A .Review of a case report: Long-term Supression Of Bone Marrow With Prolonged Pancytopenia After Ibritumomab Tiuxetan In Jehovah's Witness Patient With Relapsed Follicular Non-hodgkin's Lymphoma [Review of the article 'Long-term Supression Of Bone Marrow With Prolonged Pancytopenia After Ibritumomab Tiuxetan In Jehovah's Witness Patient With Relapsed Follicular Non-hodgkin's Lymphoma ' by Greksak R].WebmedCentral 2011;2(11):WMCRW001129

Rating
Rating	1	2	3	4	5	6	7	8	9

Report abuse